Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer

Lung Cancer. 2017 Sep:111:65-68. doi: 10.1016/j.lungcan.2017.07.012. Epub 2017 Jul 11.

Abstract

Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.

Keywords: Adenocarcinoma; EGFR; NSCLC; Nivolumab; Small cell lung cancer; Transformation.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biopsy
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Cell Transformation, Neoplastic / genetics*
  • Disease Progression
  • Drug Resistance, Neoplasm / genetics
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism*
  • Female
  • Humans
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology*
  • Middle Aged
  • Mutation*
  • Nivolumab
  • Positron Emission Tomography Computed Tomography
  • Small Cell Lung Carcinoma / diagnosis
  • Small Cell Lung Carcinoma / genetics*
  • Small Cell Lung Carcinoma / pathology*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Nivolumab
  • ErbB Receptors